Captor Therapeutics (CTX) Q3 2024 earnings summary

Executive summary

• Advanced pipeline with multiple first-in-class targeted protein degraders for oncology, autoimmune, and neurodegenerative diseases, progressing through preclinical and IND-enabling stages.

• Focus on CT-01 (GSPTI degrader for HCC, lung, and NET tumors), CT-03 (MCL-1 degrader for liquid and solid tumors), and CT-02 (NEK7 degrader for autoimmune and neurodegenerative diseases).

• Revenue from R&D services increased to PLN 12,871k for the nine months ended September 30, 2024, up from PLN 6,716k year-over-year, driven by commercial partnerships, notably with Ono Pharmaceutical.

• Net loss narrowed to PLN 29,666k from PLN 59,098k year-over-year, reflecting reduced preclinical expenditures as projects advanced to clinical stages.

• The company submitted its first Clinical Trial Authorization Application for the CT-01 program in liver cancer, marking a significant milestone.

Financial highlights

• Revenues from collaborations increased from PLN 6.7M to PLN 12.9M compared to Q3 2023.

• Grant revenues decreased from PLN 12.3M to PLN 3.7M year-over-year.

• Total consolidated revenue: PLN 17,454k (including PLN 3,659k grant revenue), down from PLN 22,173k year-over-year due to lower grant income.

• Operating expenses decreased to PLN 46,650k from PLN 70,198k, mainly due to lower third-party services and employee benefit costs.

• Net loss narrowed from PLN 59.1M to PLN 29.7M due to prioritization of lead projects and cost management.

• Operational cash outflow reduced from PLN 34.9M in Q3 2023 to PLN 23.6M in Q3 2024.

Outlook and guidance

• Cash runway secured until Q3 2025 based on current guidance and available funding.

• Management expects continued losses as R&D projects progress but anticipates further revenue growth from partnerships and new grant opportunities.

• Additional funding sources, including grants and potential capital raises, are being pursued to support operations beyond 2025.

• The board is confident in the company’s ability to meet obligations for at least 12 months from the approval date.